Natarajan Ravendhran

Author

Digestive Care (United States)

Also Known As

N. Ravendhran, Natarajan Ravendhran, Vlad Ratziu

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

Digestive Care (United States)University of Miami Johns Hopkins University Cedars-Sinai Medical Center Indiana University – Purdue University Indianapolis

About

Natarajan Ravendhran is an author at Digestive Care (United States) specializing in viral hepatitis, medicine, and hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	1.9K
2	Hepatology	9	10	1.8K
3	Health Sciences	2	3	887
4	Epidemiology	2	2	61
5	Immunology	2	2	30

Natarajan Ravendhran

Publications

Citations

H-Index

Page 1

	Year	Citations
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Paul Y. Kwo, Eric Lawitz, Jonathan McCone, The Lancet HepatologyHepatitis CViral HepatitisNs3 Protease InhibitorAntiviral Drug Development	2010	703
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study David R. Nelson, James N. Cooper, Jacob Lalezari, Hepatology	2015	688
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection Marc Bourlière, Stuart C. Gordon, Steven L. Flamm, New England Journal of Medicine	2017	558
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue, Journal of Hepatology FibrosisHepatologyLiver PhysiologyClinical TrialsPathology	2020	438
4 HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT- NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C Paul Y. Kwo, E. Läwitz, Jonathan McCone, Journal of Hepatology A Phase 2Viral PersistenceHepatologyHepatitis CSvr 24	2009	86
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study Rohit Loomba, Arun J. Sanyal, Atsushi Nakajima, Clinical Gastroenterology and Hepatology	2023	78
Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data Julius Wilder, Lennox J. Jeffers, Natarajan Ravendhran, Hepatology	2015	58
Racial differences in hepatitis C treatment eligibility Michael T. Melia, Andrew J. Muir, Jonathan McCone, Hepatology	2011	50
995 INTERIM RESULTS FROM HCV SPRINT-1: RVR/EVR FROM PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRONTM (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHC Paul Y. Kwo, E. Läwitz, Jonathan McCone, Journal of Hepatology Viral PersistenceViral HepatitisAntiviral TherapyHepatitisVirology	2008	45
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection Mark Sulkowski, Kosh Agarwal, Xiaoli Ma, Journal of Hepatology	2022	38

Page 1